[Drugs for hepatitis B and C infection].
Iino
Shiro
S
Seizankai Kiyokawa Hospital.
D000225:Adenine / Q000008:administration & dosage / Q000031:analogs & derivatives; D000998:Antiviral Agents / Q000008:administration & dosage; D004359:Drug Therapy, Combination; D006147:Guanine / Q000008:administration & dosage / Q000031:analogs & derivatives; D006509:Hepatitis B / Q000188:drug therapy*; D006515:Hepatitis B virus / Q000235:genetics; D006526:Hepatitis C / Q000188:drug therapy*; D006801:Humans; D019259:Lamivudine / Q000008:administration & dosage; D009154:Mutation; D009842:Oligopeptides / Q000008:administration & dosage; D063065:Organophosphonates / Q000008:administration & dosage; D011392:Proline / Q000008:administration & dosage / Q000031:analogs & derivatives; D012254:Ribavirin / Q000031:analogs & derivatives; D015842:Serine Proteinase Inhibitors / Q000008:administration & dosage
D000998:Antiviral Agents; D009842:Oligopeptides; D063065:Organophosphonates; D015842:Serine Proteinase Inhibitors; D019259:Lamivudine; D012254:Ribavirin; C413685:entecavir; D006147:Guanine; C486464:telaprevir; C053001:adefovir; C512204:N-(3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl)-3-(2-((((1,1-dimethylethyl)amino)carbonyl)amino)-3,3-dimethyl-1-oxobutyl)-6,6-dimethyl-3-azabicyclo(3.1.0)hexan-2-carboxamide; D011392:Proline; D000225:Adenine; C026956:taribavirin